These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30076542)

  • 1. Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis.
    Kim MJ; Lee EE; Lee EY; Song YW; Yu HG; Choi Y; Lee EB
    Clin Rheumatol; 2018 Oct; 37(10):2763-2770. PubMed ID: 30076542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
    Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
    Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis.
    Wu D; Guo YY; Xu NN; Zhao S; Hou LX; Jiao T; Zhang N
    BMC Musculoskelet Disord; 2015 Feb; 16(1):19. PubMed ID: 25888248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
    Lee S; Park YJ; Lee JY
    J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) - an open-label randomized controlled multicenter trial.
    Proft F; Muche B; Listing J; Rios-Rodriguez V; Sieper J; Poddubnyy D
    BMJ Open; 2017 Jun; 7(6):e014591. PubMed ID: 28601821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-α inhibitors.
    Carbo MJG; Spoorenberg A; Maas F; Brouwer E; Bos R; Bootsma H; van der Veer E; Wink F; Arends S
    PLoS One; 2018; 13(4):e0196281. PubMed ID: 29689112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study.
    Závada J; Uher M; Sisol K; Forejtová Š; Jarošová K; Mann H; Vencovský J; Pavelka K
    Ann Rheum Dis; 2016 Jan; 75(1):96-102. PubMed ID: 25165033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study.
    Bae JM; Kim M; Lee HH; Kim KJ; Shin H; Ju HJ; Kim GM; Park CJ; Park HJ
    J Invest Dermatol; 2018 Apr; 138(4):768-774. PubMed ID: 29175284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
    Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
    Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-steroidal anti-inflammatory drugs in patients with stable ankylosing spondylitis receiving tumor necrosis factor inhibitor: continued vs withdrawn.
    Park JH; Kwon OC; Park MC
    Clin Rheumatol; 2020 Dec; 39(12):3669-3675. PubMed ID: 32447601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Systemically Used Anti-Tumor Necrosis Factor-α Medication on the Corneal Epithelium and Stroma of Patients with Ankylosing Spondylitis.
    Arikan S; Gokmen F; Ersan I; Akbal A; Resorlu H; Gencer B; Ali Tufan H; Kara S
    Ocul Immunol Inflamm; 2017 Apr; 25(2):223-228. PubMed ID: 26731089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
    Braun J; Baraliakos X; Listing J; Sieper J
    Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Response to anti-TNF-alpha treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis].
    Bellissimo S; Ferrucci MG; Gallo A; Stisi S
    Reumatismo; 2007; 59(3):240-3. PubMed ID: 17898885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients.
    Choi EY; Lee M; Lee CS
    Clin Exp Rheumatol; 2020; 38(6):1132-1137. PubMed ID: 32828140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art.
    Fabiani C; Vitale A; Lopalco G; Iannone F; Frediani B; Cantarini L
    Clin Rheumatol; 2016 Nov; 35(11):2631-2638. PubMed ID: 27686662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-α treatment? Case report and literature review.
    Psarelis S; Hajineocli APD; Hadjicosta E; Elliott HSA; Johnson P
    Clin Rheumatol; 2017 May; 36(5):1197-1199. PubMed ID: 28233109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis.
    Chitul A; Voiosu AM; Marinescu M; Caraiola S; Nicolau A; Badea GC; Pârvu MI; Ionescu RA; Mateescu BR; Voiosu MR; Băicuş CR; Rimbaş M
    Rom J Intern Med; 2017 Mar; 55(1):44-52. PubMed ID: 28103201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
    Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.